SCHMC

한국형 양극성 장애 약물치표 알고리듬 2018 : 안정성과 내약성

Metadata Downloads
Alternative Title
Korean Medication Algorithm for Bipolar Disorder 2018 : Safety and Tolerability
Abstract
Objectives : Treatment for bipolar disorder is often complicated by various clinical situations. We undertook a survey of expert opinions to facilitate clinical decisions in special situations such as weight gain, metabolic syndrome, hyperprolactinemia, genetic counseling, and treatment adherence.
Methods : A written survey that asked treatment strategies related to safety and tolerability, was prepared focused on weight gain, antipsychotic related hyperprolactinemia, lamotrigine related skin rash, treatment non-adherence and genetic counseling. Sixty-one experts of the review committee completed the survey.
Results : In the case of weight gain related to medications, experts preferred exercise and education for diet-control. First chosen medications were lamotrigine, aripiprazole and ziprasidone. Recommendations based on expert survey results for treatment of bipolar patients in other special situations are outlined.
Conclusion : With limitation of expert opinions, authors hope that results of this study provide valuable information to make clinical decisions about treatment of bipolar disorder in complicated situations.
All Author(s)
I. Sohn ; W. M. Bahk ; B. H. Yoon ; D. I. Jon ; J. S. Seo ; W. Kim ; J. G. Lee ; Y. S. Woo ; J. H. Jeong ; M. D. Kim ; Y. E. Jung ; S. H. Shim ; H. R. Song ; K. J. Min
Issued Date
2018
Type
Article
Keyword
Bipolar disorderWeight gainNon-adherenceLamotrigineHyperprolactinemiaGenetic counsellingAlgorithm
Publisher
대한우울조울병학회
Korean Society for Affective Disorders
ISSN
1738-0960 ; 2671-4655
Citation Title
Mood and Emotion
Citation Volume
16
Citation Number
3
Citation Start Page
134
Citation End Page
139
Language(ISO)
kor
URI
http://schca-ir.schmc.ac.kr/handle/2022.oak/2481
Appears in Collections:
정신건강의학과 > 1. Journal Papers
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.